Cargando…
Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy
BACKGROUND: It is unclear whether asthma and asthma medications increase or decrease the risk of severe COVID-19, and this is particularly true for patients with severe asthma receiving biologics. OBJECTIVES: The aim of this study was to assess incidence and disease course of COVID-19 in patients wi...
Autores principales: | Eger, Katrien, Hashimoto, Simone, Braunstahl, Gert Jan, Brinke, Anneke ten, Patberg, Kornelis W., Beukert, Annelies, Smeenk, Frank, van der Sar–van der Brugge, Simone, Weersink, Els J.M., Bel, Elisabeth H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833566/ https://www.ncbi.nlm.nih.gov/pubmed/33388603 http://dx.doi.org/10.1016/j.rmed.2020.106287 |
Ejemplares similares
-
Targeting dynamic hyperinflation in moderate-to-severe asthma: a randomised controlled trial
por: van der Meer, Akke-Nynke, et al.
Publicado: (2021) -
Management of the patient with eosinophilic asthma: a new era begins
por: de Groot, Jantina C., et al.
Publicado: (2015) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017) -
Asthma and COVID-19: do we finally have answers?
por: Eger, Katrien, et al.
Publicado: (2021) -
Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma
por: Kroes, Johannes A., et al.
Publicado: (2022)